Relationship of the CD22 immunotoxin dose and the tumour establishment in a SCID mice model

Leukemia and Lymphoma

Volumn 39, Issue 5-6, 2000, Pages 591-599

  van Horssen, P J ^a   Preijers, F W M B ^a   van Oostehout, Y V J M ^a   Eling, W M C ^a   de Witte, T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CD22 Ricin A; Chloroquine; Dose schedule; SCID model; Tumour load; Tumour localisation

Indexed keywords

ALANINE AMINOTRANSFERASE; CD22 ANTIGEN; CHLOROQUINE; CREATINE KINASE; IMMUNOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD22; RECOMBINANT PROTEIN; RICIN A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CELL MIGRATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; HINDLIMB; HUMAN; HUMAN CELL; IN VIVO STUDY; INOCULATION; LIVER TOXICITY; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; OSMOTIC PUMP; PARALYSIS; PRIORITY JOURNAL; SCID MOUSE; SOLID TUMOR; TARGET CELL; TIME; TUMOR CELL; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR XENOGRAFT; WEIGHT REDUCTION;

EID: 0034486997     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009113389     Document Type: Article

References (34)

1. Immunotoxins: An update
2. Rationale for the clinical use of immunotoxins: Monoclonal antibodies conjugated to ribosome-inactivating proteins
3. Ribosome-inactivating proteins up to date
4. Molecular mechanisms regulating CD19, CD20 and CD22 gene expression
5. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas
6. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice
7. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: Effect on tumor cells in extranodal sites
8. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy
9. Cytotoxic potency of CD22-ricin A depends on intracellular routing rather than on the number of internalized molecules
10. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice
11. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin
12. Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail
13. Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies
14. Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma
15. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains
16. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy
17. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study
18. Phase I immunotoxin trial in patients with B-cell lymphoma
19. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin
20. Immunotoxins for the treatment of B-cell lymphomas
21. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages
22. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo
23. Recent developments in immunotoxin therapy
24. Enhancement of immunotoxin activity using chemical and biological reagents
25. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone
26. Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombination ricin A
27. Inhibition of catabolism of radiolabeled antibodies by tumor cells using lysosomotropic amines and carboxylic ionophores
28. Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients
29. Pharmacokinetic considerations on monoclonal antibodies
30. Immunotoxin therapy of lymphoid neoplasms
31. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: Implications for vascular leak syndrome
32. Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores
33. Recombinant ricin A chain conjugated to monoclonal anti-bodies: Improved tumor cell inhibition in the presence of lysosomotropic compounds
34. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice